MP-02.01
RSPH9 Methylation Pattern as a Prognostic Indicator in Patients with Non-Muscle Invasive Bladder Cancer
Yong-June Kim, South Korea

MP-02.02
Prospective Evaluation of Urinary Survivin Levels as a Potential Prognostic and Predictive Biomarker in Non-Muscle Invasive Bladder Cancer Cases on Intravesical BCG Therapy
Harvinder Singh, India

MP-02.03
Natural Resistance-Associated Macrophage Protein 1 and Bladder Cancer Immunotherapy in Asian Patients
Ziting Wang, Singapore

MP-02.04
Swedish National Register for Urinary Bladder Cancer: No Difference in Relative Survival of Bladder Cancer over Time
Per-Uno Malmström, Sweden

MP-02.05
Human Serum Based Proteometabolomic Approach for Appraisal of Low- and High-Grade Bladder Cancer
Saurabh Gupta, India

MP-02.06
Microscopic Hematuria Screening in a Male Consumer Population with Lower Urinary Tract Symptoms
Claus Roehrborn, USA

MP-02.07
Value of NBI in the Non-Invasive Bladder Cancer Follow-Up
Petrisor Geavlete, Romania

MP-02.08
An Initial Comparative Evaluation in NMIBC Endoscopic Imaging: SPIES versus NBI Technology
Petrisor Geavlete, Romania

MP-02.09
En-Block Plasma-Button Resection in NMIBC Endoscopic Treatment
Petrisor Geavlete, Romania

MP-02.10
The New Application of Narrow Band Imaging for Transurethral Enblock Dissection of Bladder Tumors
Yohei Okada, Japan
**MP-02.11**
Randomized Study of One-Year Maintenance Intravesical Bacillus Calmette-Guerin Treatment for High-Risk Non-Muscle Invasive Bladder Cancer
Fuminori Sato, Japan

**MP-02.12**
Bacillus Calmette-Guerin (BCG) Intolerance Is a Significant Predictive Factor in Non-Complete Response and Progression in BCG Therapy for Non-Muscle Invasive Bladder Cancer: Evidence from a Randomized Control Trial
Akira Yokomizo, Japan

**MP-02.13**
Intravesical Bacillus Calmette-Guerin for Non-Muscle Invasive Urothelial Carcinoma of the Bladder: Patterns of Use and Impact on Outcomes
Sarah Azer, Australia